# US 2025/0145733 A1 · Tumor-specific bispecific immune cell engager

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0145733 A1
- Document ID: US20250145733A1
- Status: Published application
- Kind: A1
- Application number: 18/693,921
- Filed: 2022-09-21
- Published: 2025-05-08
- Earliest claimed: 2021-09-22
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: Bin Liu; Scott Bidlingmaier; Yang Su
- Web page: https://patentgrep.com/patent/US20250145733A1

## CPC

- C07K 16/40: against enzymes
- A61P 35/00: Antineoplastic agents
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- C12Y 301/03001: Alkaline phosphatase (3.1.3.1)
- G01N 33/575: for cancer
- C07K 2317/21: from primates, e.g. man
- C07K 2317/31: multispecific
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/64: comprising a combination of variable region and constant region components
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Disclosed herein are monospecific and bispecific antibodies that comprise a ALPPL2/ALPP-binding variable region. The bi-specific antibody is comprises of a monoclonal antibody targeting a tumor-specific cell surface antigen (ALPPL2/ALPP) with exquisite tissue specificity and a monoclonal antibody targeting a cell surface molecule (e.g., CD3) expressed by immune effector cells.

## Claims

### Claim 1

An antibody comprising a variable region that specifically binds to ALPPL2 and ALPP, wherein the antibody comprises a heavy chain variable region and a light chain variable region,
wherein complementarity determining region (CDR) 1, CDR2 and CDR3 of the heavy chain variable region are selected from the following sets:
SEQ ID NOs: 20, 21, and 22;
SEQ ID NOs: 23, 24, and 25;
SEQ ID NOs: 26, 27, and 28;
SEQ ID NOs: 29, 30, and 31;
SEQ ID NOs: 32, 33, and 34;
SEQ ID NOs: 35, 36, and 37;
SEQ ID NOs: 38, 39, and 40;
SEQ ID NOs: 41, 42, and 43;
SEQ ID NOs: 44, 45, and 46;
SEQ ID NOs: 47, 48, and 49; or
SEQ ID NOs: 50, 51, and 52;
CDR1, CDR2, and CDR3 of the light chain variable region are selected from the following sets:
SEQ ID NOs: 53, 54, and 55;
SEQ ID NOs: 56, 57, and 58;
SEQ ID NOs: 59, 60, and 61;
SEQ ID NOs: 62, 63, and 64;
SEQ ID NOs: 65, 66, and 67;
SEQ ID NOs: 68, 69, and 70;
SEQ ID NOs: 71, 72, and 73; or
SEQ ID NOs: 74, 75, and 76,
with the proviso that the antibody does not have the heavy chain variable region of M25FYIA and the light chain variable region of M25FYIA.

### Claim 2 (depends on 1)

The antibody of claim 1, wherein
CDR1, CDR2, and CDR3 of the heavy chain variable region comprise SEQ ID NO: 23, SEQ ID NO: 24, and SEQ ID NO: 25, respectively; and
CDR1, CDR2, and CDR3 of the light chain variable region comprise SEQ ID NO: 56, SEQ ID NO: 57, and SEQ ID NO: 58, respectively; or
CDR1, CDR2, and CDR3 of the heavy chain variable region comprise SEQ ID NO: 26, SEQ ID NO: 27, and SEQ ID NO: 28, respectively; and
CDR1, CDR2, and CDR3 of the light chain variable region comprise SEQ ID NO: 56, SEQ ID NO: 57, and SEQ ID NO: 58, respectively; or
CDR1, CDR2, and CDR3 of the heavy chain variable region comprise SEQ ID NO: 44, SEQ ID NO: 45, and SEQ ID NO: 46, respectively; and
CDR1, CDR2, and CDR3 of the light chain variable region comprise SEQ ID NO: 71, SEQ ID NO: 72, and SEQ ID NO: 73, respectively; or
CDR1, CDR2, and CDR3 of the heavy chain variable region comprise SEQ ID NO: 38, SEQ ID NO: 39, and SEQ ID NO: 40, respectively; and
CDR1, CDR2, and CDR3 of the light chain variable region comprise SEQ ID NO: 65, SEQ ID NO: 66, and SEQ ID NO: 67, respectively; or
CDR1, CDR2, and CDR3 of the heavy chain variable region comprise SEQ ID NO: 41, SEQ ID NO: 42, and SEQ ID NO: 43, respectively; and
CDR1, CDR2, and CDR3 of the light chain variable region comprise SEQ ID NO: 53, SEQ ID NO: 54, and SEQ ID NO: 55, respectively; or
CDR1, CDR2, and CDR3 of the heavy chain variable region comprise SEQ ID NO: 35, SEQ ID NO: 36, and SEQ ID NO: 37, respectively; and
CDR1, CDR2, and CDR3 of the light chain variable region comprise SEQ ID NO: 59, SEQ ID NO: 60, and SEQ ID NO: 61, respectively.

### Claim 3 (depends on 1, 2)

The antibody of any one of claim 1-2, wherein
the heavy chain variable region is selected from the group consisting of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11.

### Claim 4 (depends on 1, 2, 3)

The antibody of any one of claim 1-3, wherein
the light chain variable region is selected from the group consisting of SEQ ID NOs: 12, 13, 14, 15, 16, 17, 18, and 19.

### Claim 5 (depends on 1)

The antibody of claim 1, wherein
the heavy chain variable region comprises SEQ ID NO: 1; and
the light chain variable region comprises SEQ ID NO: 12; or
the heavy chain variable region comprises SEQ ID NO: 2; and
the light chain variable region comprises SEQ ID NO: 13; or
the heavy chain variable region comprises SEQ ID NO: 3; and
the light chain variable region comprises SEQ ID NO: 13; or
the heavy chain variable region comprises SEQ ID NO: 9; and
the light chain variable region comprises SEQ ID NO: 18; or
the heavy chain variable region comprises SEQ ID NO: 1; and
the light chain variable region comprises SEQ ID NO: 12; or
the heavy chain variable region comprises SEQ ID NO: 7; and
the light chain variable region comprises SEQ ID NO: 16; or
the heavy chain variable region comprises SEQ ID NO: 8; and
the light chain variable region comprises SEQ ID NO: 12; or
the heavy chain variable region comprises SEQ ID NO: 6; and
the light chain variable region comprises SEQ ID NO: 14.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The antibody of any one of claims 1-5, wherein the antibody is an IgG, IgA or IgE antibody.

### Claim 7 (depends on 6)

The antibody of claim 6, wherein the antibody is an IgG antibody.

### Claim 8 (depends on 7)

The antibody of claim 7, wherein the antibody is an IgG1, IgG2, IgG3, or IgG4 antibody.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The antibody of any one of claims 1-8, wherein the antibody is a monospecific antibody.

### Claim 10 (depends on 9)

The antibody of claim 9, wherein the antibody is linked to a cytotoxic agent.

### Claim 11 (depends on 10)

The antibody of claim 10, wherein the cytotoxic agent is a radionucleotide.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The antibody of any one of claims 1-8, wherein the antibody is a bi-specific antibody comprising a second variable region that specifically binds to a second target protein, wherein the antibody comprises a second heavy chain variable region and a second light chain variable region.

### Claim 13 (depends on 12)

The antibody of claim 12, wherein the second target protein is expressed on the surface of a human immune effector cell.

### Claim 14 (depends on 12)

The antibody of claim 12, wherein the second target protein is human CD3.

### Claim 15 (depends on 14)

The antibody of claim 14, wherein the CDR1, CDR2, and CDR3 of the second heavy chain variable region comprise SEQ ID NO: 79, SEQ ID NO: 80 and SEQ ID NO: 81 and the CDR1, CDR2, and CDR3 of the second light chain variable region comprise SEQ ID NO: 82, SEQ ID NO: 83 and SEQ ID NO: 84.

### Claim 16 (depends on 14)

The antibody of claim 14, wherein the second heavy chain variable region comprises SEQ ID NO: 77 and the second light chain variable region comprises SEQ ID NO:78.

### Claim 17 (depends on 14)

The antibody of claim 14, comprising SEQ ID NO:85 and SEQ ID NO:86.

### Claim 18 (depends on 14)

The antibody of claim 14, comprising SEQ ID NO:87 and SEQ ID NO:88.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

A pharmaceutical composition comprising the antibody of any one of claims 1-18.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

A nucleic acid encoding the antibody of any one of claims 1-18.

### Claim 21 (depends on 20)

A vector comprising the nucleic acid sequence of claim 20.

### Claim 22 (depends on 20, 21)

A cell comprising the nucleic acid of claim 20 or the vector of claim 21.

### Claim 23 (depends on 22)

The cell of claim 22, wherein the cell is a mammalian cell.

### Claim 24 (depends on 22, 23)

A method for producing an antibody, the method comprising culturing the cell of any one of claim 22 or 23 under conditions to allow for production of the antibody.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

A method of killing a cancer cell, the method comprising, contacting the antibody of any one of claims 1-18 to a cancer cell.

### Claim 26 (depends on 25)

The method of claim 25, wherein the antibody is a bi-specific antibody comprising a second variable region that specifically binds to a second target protein, wherein the second target protein is human CD3, wherein the antibody comprises a second heavy chain variable region and a second light chain variable region, and wherein the cancer cell is brought in proximity to a peripheral blood mononuclear cell (PBMC) expressing CD3 by binding of the antibody.

### Claim 27 (depends on 26)

The method of claim 26, wherein the PBMC is a T-cell.

### Claim 28 (depends on 26)

The method of claim 26, wherein the CDR1, CDR2, and CDR3 of the second heavy chain variable region comprise SEQ ID NO: 79, SEQ ID NO: 80 and SEQ ID NO: 81 and the CDR1, CDR2, and CDR3 of the second light chain variable region comprise SEQ ID NO: 82, SEQ ID NO: 83 and SEQ ID NO: 84.

### Claim 29 (depends on 28)

The method of claim 28, wherein the second heavy chain variable region comprises SEQ ID NO: 77 and the second light chain variable region comprises SEQ ID NO:78.

### Claim 30 (depends on 28)

The method of claim 28, wherein the antibody comprises SEQ ID NO:85 and SEQ ID NO:86.

### Claim 31 (depends on 28)

The method of claim 28, wherein the antibody comprises SEQ ID NO:87 and SEQ ID NO:88.

### Claim 32 (depends on 25)

The method of claim 25, wherein the antibody is linked to a cytotoxic agent.

### Claim 33 (depends on 32)

The method of claim 32, wherein the cytotoxic agent is a radionucleotide.

### Claim 34 (depends on 25, 26, 27, 28, 29, 30, 31, 32)

The method of any one of claims 25-32, wherein the cancer cell is in a human having the cancer cell and the antibody is administered to the human, thereby killing the cancer cell.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A chimeric antigen receptor (CAR)-expressing human cell, wherein the CAR comprises the heavy chain variable region and the light chain variable region of any one of claims 1-9.

### Claim 36 (depends on 36)

The CAR-expressing human cell of claim 36, wherein the human cell is a T-cell, natural killer cell or a macrophage.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

A method of detecting a tumor cell in a sample, the method comprising contacting an antibody of any one of claims 1-18 to the sample; and
detecting specific binding of the antibody to the tumor cell.
